TY - JOUR AU - Ye, B. AU - Stary, C. M. AU - Li, X. AU - Gao, Q. AU - Kang, C. AU - Xiong, X. PY - 2018 DA - 2018// TI - Engineering chimeric antigen receptor-T cells for cancer treatment JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0814-0 DO - 10.1186/s12943-018-0814-0 ID - Ye2018 ER - TY - JOUR AU - Yu, S. AU - Li, A. AU - Liu, Q. AU - Li, T. AU - Yuan, X. AU - Han, X. PY - 2017 DA - 2017// TI - Chimeric antigen receptor T cells: a novel therapy for solid tumors JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0444-9 DO - 10.1186/s13045-017-0444-9 ID - Yu2017 ER - TY - JOUR AU - Yu, S. AU - Liu, Q. AU - Han, X. AU - Qin, S. AU - Zhao, W. AU - Li, A. PY - 2017 DA - 2017// TI - Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment JO - Exp Hematol Oncol VL - 6 UR - https://doi.org/10.1186/s40164-017-0091-4 DO - 10.1186/s40164-017-0091-4 ID - Yu2017 ER - TY - JOUR AU - Crist, M. AU - Balar, A. PY - 2017 DA - 2017// TI - Atezolizumab in invasive and metastatic urothelial carcinoma JO - Expert Rev Clin Pharmacol VL - 10 UR - https://doi.org/10.1080/17512433.2017.1389275 DO - 10.1080/17512433.2017.1389275 ID - Crist2017 ER - TY - JOUR AU - Kythreotou, A. AU - Siddique, A. AU - Mauri, F. A. AU - Bower, M. AU - Pinato, D. J. PY - 2018 DA - 2018// TI - PD-L1 JO - J Clin Pathol VL - 71 UR - https://doi.org/10.1136/jclinpath-2017-204853 DO - 10.1136/jclinpath-2017-204853 ID - Kythreotou2018 ER - TY - JOUR AU - Boussiotis, V. A. AU - Chatterjee, P. AU - Li, L. PY - 2014 DA - 2014// TI - Biochemical signaling of PD-1 on T cells and its functional implications JO - Cancer J VL - 20 UR - https://doi.org/10.1097/PPO.0000000000000059 DO - 10.1097/PPO.0000000000000059 ID - Boussiotis2014 ER - TY - STD TI - Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5 ra46 ID - ref7 ER - TY - JOUR AU - LaFleur, M. W. AU - Muroyama, Y. AU - Drake, C. G. AU - Sharpe, A. H. PY - 2018 DA - 2018// TI - Inhibitors of the PD-1 pathway in tumor therapy JO - J Immunol VL - 200 UR - https://doi.org/10.4049/jimmunol.1701044 DO - 10.4049/jimmunol.1701044 ID - LaFleur2018 ER - TY - JOUR AU - Dougan, M. PY - 2017 DA - 2017// TI - Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01547 DO - 10.3389/fimmu.2017.01547 ID - Dougan2017 ER - TY - JOUR AU - Kuol, N. AU - Stojanovska, L. AU - Nurgali, K. AU - Apostolopoulos, V. PY - 2018 DA - 2018// TI - PD-1/PD-L1 in disease JO - Immunotherapy VL - 10 UR - https://doi.org/10.2217/imt-2017-0120 DO - 10.2217/imt-2017-0120 ID - Kuol2018 ER - TY - JOUR AU - Juchem, K. W. AU - Sacirbegovic, F. AU - Zhang, C. AU - Sharpe, A. H. AU - Russell, K. AU - McNiff, J. M. PY - 2018 DA - 2018// TI - PD-L1 prevents the development of autoimmune heart disease in graft-versus-host disease JO - J Immunol VL - 200 UR - https://doi.org/10.4049/jimmunol.1701076 DO - 10.4049/jimmunol.1701076 ID - Juchem2018 ER - TY - JOUR AU - Zhang, J. AU - Bu, X. AU - Wang, H. AU - Zhu, Y. AU - Geng, Y. AU - Nihira, N. T. PY - 2018 DA - 2018// TI - Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance JO - Nature VL - 553 UR - https://doi.org/10.1038/nature25015 DO - 10.1038/nature25015 ID - Zhang2018 ER - TY - JOUR AU - Ribas, A. PY - 2015 DA - 2015// TI - Adaptive immune resistance: how Cancer protects from immune attack JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0563 DO - 10.1158/2159-8290.CD-15-0563 ID - Ribas2015 ER - TY - JOUR AU - Witt, D. A. AU - Donson, A. M. AU - Amani, V. AU - Moreira, D. C. AU - Sanford, B. AU - Hoffman, L. M. PY - 2018 DA - 2018// TI - Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: implications for PD-1-targeted therapy JO - Pediatr Blood Cancer VL - 65 UR - https://doi.org/10.1002/pbc.26960 DO - 10.1002/pbc.26960 ID - Witt2018 ER - TY - JOUR AU - Zheng, B. AU - Ren, T. AU - Huang, Y. AU - Sun, K. AU - Wang, S. AU - Bao, X. PY - 2018 DA - 2018// TI - PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0560-1 DO - 10.1186/s13045-018-0560-1 ID - Zheng2018 ER - TY - JOUR AU - Xu-Monette, Z. Y. AU - Zhang, M. AU - Li, J. AU - Young, K. H. PY - 2017 DA - 2017// TI - PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01597 DO - 10.3389/fimmu.2017.01597 ID - Xu-Monette2017 ER - TY - JOUR AU - Karlsson, A. K. AU - Saleh, S. N. PY - 2017 DA - 2017// TI - Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis JO - Clin Cosmet Investig Dermatol VL - 10 UR - https://doi.org/10.2147/CCID.S120877 DO - 10.2147/CCID.S120877 ID - Karlsson2017 ER - TY - JOUR AU - Liu, B. AU - Song, Y. AU - Liu, D. PY - 2017 DA - 2017// TI - Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0541-9 DO - 10.1186/s13045-017-0541-9 ID - Liu2017 ER - TY - JOUR AU - Alsaab, H. O. AU - Sau, S. AU - Alzhrani, R. AU - Tatiparti, K. AU - Bhise, K. AU - Kashaw, S. K. PY - 2017 DA - 2017// TI - PD-1 and PD-L1 checkpoint signaling inhibition for Cancer immunotherapy: mechanism, combinations, and clinical outcome JO - Front Pharmacol VL - 8 UR - https://doi.org/10.3389/fphar.2017.00561 DO - 10.3389/fphar.2017.00561 ID - Alsaab2017 ER - TY - STD TI - Jindal V, Gupta S. Expected paradigm shift in brain metastases therapy-immune checkpoint inhibitors. Mol Neurobiol. 2018; https://doi.org/10.1007/s12035-018-0905-3. ID - ref20 ER - TY - JOUR AU - Jenkins, R. W. AU - Barbie, D. A. AU - Flaherty, K. T. PY - 2018 DA - 2018// TI - Mechanisms of resistance to immune checkpoint inhibitors JO - Br J Cancer VL - 118 UR - https://doi.org/10.1038/bjc.2017.434 DO - 10.1038/bjc.2017.434 ID - Jenkins2018 ER - TY - JOUR AU - Polk, A. AU - Svane, I. M. AU - Andersson, M. AU - Nielsen, D. PY - 2017 DA - 2017// TI - Checkpoint inhibitors in breast cancer - current status JO - Cancer Treat Rev VL - 63 UR - https://doi.org/10.1016/j.ctrv.2017.12.008 DO - 10.1016/j.ctrv.2017.12.008 ID - Polk2017 ER - TY - JOUR AU - Sheng, Z. AU - Zhu, X. AU - Sun, Y. AU - Zhang, Y. PY - 2017 DA - 2017// TI - The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer JO - Oncotarget VL - 8 ID - Sheng2017 ER - TY - JOUR AU - Ancevski Hunter, K. AU - Socinski, M. A. AU - Villaruz, L. C. PY - 2018 DA - 2018// TI - PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung Cancer JO - Mol Diagn Ther VL - 22 UR - https://doi.org/10.1007/s40291-017-0308-6 DO - 10.1007/s40291-017-0308-6 ID - Ancevski Hunter2018 ER - TY - JOUR AU - Janjigian, Y. Y. AU - Sanchez-Vega, F. AU - Jonsson, P. AU - Chatila, W. K. AU - Hechtman, J. F. AU - Ku, G. Y. PY - 2018 DA - 2018// TI - Genetic predictors of response to systemic therapy in Esophagogastric Cancer JO - Cancer Discov. VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-0787 DO - 10.1158/2159-8290.CD-17-0787 ID - Janjigian2018 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Li, X. AU - Shao, C. AU - Shi, Y. AU - Han, W. PY - 2018 DA - 2018// TI - Lessons learned from the blockade of immune checkpoints in cancer immunotherapy JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0578-4 DO - 10.1186/s13045-018-0578-4 ID - Li2018 ER - TY - JOUR AU - Reck, M. AU - Rodriguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csoszi, T. AU - Fulop, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Ding, W. AU - LaPlant, B. R. AU - Call, T. G. AU - Parikh, S. A. AU - Leis, J. F. AU - He, R. PY - 2017 DA - 2017// TI - Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2017-02-765685 DO - 10.1182/blood-2017-02-765685 ID - Ding2017 ER - TY - JOUR AU - Balar, A. V. AU - Castellano, D. AU - O'Donnell, P. H. AU - Grivas, P. AU - Vuky, J. AU - Powles, T. PY - 2017 DA - 2017// TI - First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30616-2 DO - 10.1016/S1470-2045(17)30616-2 ID - Balar2017 ER - TY - JOUR AU - Sharma, P. AU - Callahan, M. K. AU - Bono, P. AU - Kim, J. AU - Spiliopoulou, P. AU - Calvo, E. PY - 2016 DA - 2016// TI - Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30496-X DO - 10.1016/S1470-2045(16)30496-X ID - Sharma2016 ER - TY - JOUR AU - Liu, D. AU - Wang, S. AU - Bindeman, W. PY - 2017 DA - 2017// TI - Clinical applications of PD-L1 bioassays for cancer immunotherapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0479-y DO - 10.1186/s13045-017-0479-y ID - Liu2017 ER - TY - JOUR AU - Hirsch, F. R. AU - McElhinny, A. AU - Stanforth, D. AU - Ranger-Moore, J. AU - Jansson, M. AU - Kulangara, K. PY - 2017 DA - 2017// TI - PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.2228 DO - 10.1016/j.jtho.2016.11.2228 ID - Hirsch2017 ER - TY - STD TI - Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, et al. Impaired tumor-infiltrating T cells in patients with COPD impacts lung Cancer response to PD-1 blockade. Am J Respir Crit Care Med. 2018; https://doi.org/10.1164/rccm.201706-1110OC. ID - ref34 ER - TY - JOUR AU - Li, D. AU - Chen, R. AU - Wang, Y. W. AU - Fornace, A. J. AU - Li, H. H. PY - 2017 DA - 2017// TI - Prior irradiation results in elevated programmed cell death protein 1 (PD-1) in T cells JO - Int J Radiat Biol VL - 94 UR - https://doi.org/10.1080/09553002.2017.1400192 DO - 10.1080/09553002.2017.1400192 ID - Li2017 ER - TY - JOUR AU - Vilain, R. E. AU - Menzies, A. M. AU - Wilmott, J. S. AU - Kakavand, H. AU - Madore, J. AU - Guminski, A. PY - 2017 DA - 2017// TI - Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0698 DO - 10.1158/1078-0432.CCR-16-0698 ID - Vilain2017 ER - TY - JOUR AU - Socinski, M. A. AU - Jotte, R. M. AU - Cappuzzo, F. AU - Orlandi, F. AU - Stroyakovskiy, D. AU - Nogami, N. PY - 2018 DA - 2018// TI - Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1716948 DO - 10.1056/NEJMoa1716948 ID - Socinski2018 ER - TY - JOUR AU - Bocca, P. AU - Di Carlo, E. AU - Caruana, I. AU - Emionite, L. AU - Cilli, M. AU - De Angelis, B. PY - 2017 DA - 2017// TI - Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model JO - Oncoimmunology VL - 7 UR - https://doi.org/10.1080/2162402X.2017.1378843 DO - 10.1080/2162402X.2017.1378843 ID - Bocca2017 ER - TY - JOUR AU - McDermott, D. F. AU - Huseni, M. A. AU - Atkins, M. B. AU - Motzer, R. J. AU - Rini, B. I. AU - Escudier, B. PY - 2018 DA - 2018// TI - Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0053-3 DO - 10.1038/s41591-018-0053-3 ID - McDermott2018 ER - TY - STD TI - Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 expression heterogeneity in non-small cell lung Cancer: defining criteria for harmonization between biopsy specimens and whole sections. J Thorac Oncol. 2018; https://doi.org/10.1016/j.jtho.2018.04.017. ID - ref40 ER - TY - STD TI - Gradecki SE, Grange JS, Stelow EB. Concordance of PD-L1 expression between Core biopsy and resection specimens of non-small cell lung Cancer. Am J Surg Pathol. 2018; https://doi.org/10.1097/PAS.0000000000001085. ID - ref41 ER - TY - STD TI - Kelly RJ, Zaidi AH, Smith MA, Omstead AN, Kosovec JE, Matsui D, et al. The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post Chemoradiation. Ann Surg. 2017; https://doi.org/10.1097/SLA.0000000000002410. ID - ref42 ER - TY - JOUR AU - Xing, X. AU - Guo, J. AU - Wen, X. AU - Ding, G. AU - Li, B. AU - Dong, B. PY - 2018 DA - 2018// TI - Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients JO - Oncoimmunology. VL - 7 UR - https://doi.org/10.1080/2162402X.2017.1356144 DO - 10.1080/2162402X.2017.1356144 ID - Xing2018 ER - TY - STD TI - Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal Cancer. Ann Surg. 2017; https://doi.org/10.1097/SLA.0000000000002616. ID - ref44 ER - TY - JOUR AU - Tomioka, N. AU - Azuma, M. AU - Ikarashi, M. AU - Yamamoto, M. AU - Sato, M. AU - Watanabe, K. I. PY - 2018 DA - 2018// TI - The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) JO - Breast Cancer VL - 25 UR - https://doi.org/10.1007/s12282-017-0781-0 DO - 10.1007/s12282-017-0781-0 ID - Tomioka2018 ER - TY - JOUR AU - Teng, M. W. AU - Ngiow, S. F. AU - Ribas, A. AU - Smyth, M. J. PY - 2015 DA - 2015// TI - Classifying cancers based on T-cell infiltration and PD-L1 JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-15-0255 DO - 10.1158/0008-5472.CAN-15-0255 ID - Teng2015 ER - TY - STD TI - Solomon B, Young RJ, Bressel M, Urban D, Hendry S, Thai A, et al. Prognostic significance of PD-L1(+) and CD8(+) immune cells in HPV(+) oropharyngeal squamous cell carcinoma. Cancer Immunol Res. 2018; https://doi.org/10.1158/2326-6066.CIR-17-0299. ID - ref47 ER - TY - JOUR AU - Hegde, P. S. AU - Karanikas, V. AU - Evers, S. PY - 2016 DA - 2016// TI - The where, the when, and the how of immune monitoring for Cancer immunotherapies in the era of checkpoint inhibition JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1507 DO - 10.1158/1078-0432.CCR-15-1507 ID - Hegde2016 ER - TY - JOUR AU - Mariathasan, S. AU - Turley, S. J. AU - Nickles, D. AU - Castiglioni, A. AU - Yuen, K. AU - Wang, Y. PY - 2018 DA - 2018// TI - TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells JO - Nature VL - 554 UR - https://doi.org/10.1038/nature25501 DO - 10.1038/nature25501 ID - Mariathasan2018 ER - TY - JOUR AU - Ravi, R. AU - Noonan, K. A. AU - Pham, V. AU - Bedi, R. AU - Zhavoronkov, A. AU - Ozerov, I. V. PY - 2018 DA - 2018// TI - Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-017-02696-6 DO - 10.1038/s41467-017-02696-6 ID - Ravi2018 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Dholaria, B. AU - Soyano, A. E. AU - Knutson, K. L. AU - Chumsri, S. AU - Lou, Y. PY - 2018 DA - 2018// TI - Next generation of immune checkpoint therapy in cancer: new developments and challenges JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0582-8 DO - 10.1186/s13045-018-0582-8 ID - Marin-Acevedo2018 ER - TY - STD TI - Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, et al. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018; https://doi.org/10.1002/ijc.31357. ID - ref52 ER - TY - JOUR AU - Tremblay-LeMay, R. AU - Rastgoo, N. AU - Chang, H. PY - 2018 DA - 2018// TI - Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0589-1 DO - 10.1186/s13045-018-0589-1 ID - Tremblay-LeMay2018 ER - TY - JOUR AU - Teng, F. AU - Meng, X. AU - Kong, L. AU - Yu, J. PY - 2018 DA - 2018// TI - Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review JO - Cancer Lett VL - 414 UR - https://doi.org/10.1016/j.canlet.2017.11.014 DO - 10.1016/j.canlet.2017.11.014 ID - Teng2018 ER - TY - STD TI - Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018;10 1758834017749748 ID - ref55 ER - TY - JOUR AU - Abril-Rodriguez, G. AU - Ribas, A. PY - 2017 DA - 2017// TI - SnapShot: Immune Checkpoint Inhibitors JO - Cancer Cell VL - 31 UR - https://doi.org/10.1016/j.ccell.2017.05.010 DO - 10.1016/j.ccell.2017.05.010 ID - Abril-Rodriguez2017 ER - TY - JOUR AU - Landsberg, J. AU - Kohlmeyer, J. AU - Renn, M. AU - Bald, T. AU - Rogava, M. AU - Cron, M. PY - 2012 DA - 2012// TI - Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation JO - Nature VL - 490 UR - https://doi.org/10.1038/nature11538 DO - 10.1038/nature11538 ID - Landsberg2012 ER - TY - JOUR AU - Santisteban, M. AU - Reiman, J. M. AU - Asiedu, M. K. AU - Behrens, M. D. AU - Nassar, A. AU - Kalli, K. R. PY - 2009 DA - 2009// TI - Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-3343 DO - 10.1158/0008-5472.CAN-08-3343 ID - Santisteban2009 ER - TY - JOUR AU - Baas, M. AU - Besancon, A. AU - Goncalves, T. AU - Valette, F. AU - Yagita, H. AU - Sawitzki, B. PY - 2016 DA - 2016// TI - TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance JO - elife VL - 5 UR - https://doi.org/10.7554/eLife.08133 DO - 10.7554/eLife.08133 ID - Baas2016 ER - TY - JOUR AU - Hodges, T. R. AU - Ott, M. AU - Xiu, J. AU - Gatalica, Z. AU - Swensen, J. AU - Zhou, S. PY - 2017 DA - 2017// TI - Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy JO - Neuro-Oncology VL - 19 UR - https://doi.org/10.1093/neuonc/nox026 DO - 10.1093/neuonc/nox026 ID - Hodges2017 ER - TY - JOUR AU - Rizvi, H. AU - Sanchez-Vega, F. AU - La, K. AU - Chatila, W. AU - Jonsson, P. AU - Halpenny, D. PY - 2018 DA - 2018// TI - Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung Cancer profiled with targeted next-generation sequencing JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.3384 DO - 10.1200/JCO.2017.75.3384 ID - Rizvi2018 ER - TY - JOUR AU - Goodman, A. M. AU - Kato, S. AU - Bazhenova, L. AU - Patel, S. P. AU - Frampton, G. M. AU - Miller, V. PY - 2017 DA - 2017// TI - Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0386 DO - 10.1158/1535-7163.MCT-17-0386 ID - Goodman2017 ER - TY - JOUR AU - Yuza, K. AU - Nagahashi, M. AU - Watanabe, S. AU - Takabe, K. AU - Wakai, T. PY - 2017 DA - 2017// TI - Hypermutation and microsatellite instability in gastrointestinal cancers JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.22783 DO - 10.18632/oncotarget.22783 ID - Yuza2017 ER - TY - JOUR AU - Yarchoan, M. AU - Hopkins, A. AU - Jaffee, E. M. PY - 2017 DA - 2017// TI - Tumor mutational burden and response rate to PD-1 inhibition JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMc1713444 DO - 10.1056/NEJMc1713444 ID - Yarchoan2017 ER - TY - JOUR AU - McGranahan, N. AU - Furness, A. J. AU - Rosenthal, R. AU - Ramskov, S. AU - Lyngaa, R. AU - Saini, S. K. PY - 2016 DA - 2016// TI - Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade JO - Science VL - 351 UR - https://doi.org/10.1126/science.aaf1490 DO - 10.1126/science.aaf1490 ID - McGranahan2016 ER - TY - JOUR AU - Li, G. M. PY - 2008 DA - 2008// TI - Mechanisms and functions of DNA mismatch repair JO - Cell Res VL - 18 UR - https://doi.org/10.1038/cr.2007.115 DO - 10.1038/cr.2007.115 ID - Li2008 ER - TY - JOUR AU - Kim, S. T. AU - Klempner, S. J. AU - Park, S. H. AU - Park, J. O. AU - Park, Y. S. AU - Lim, H. Y. PY - 2017 DA - 2017// TI - Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy JO - Oncotarget VL - 8 ID - Kim2017 ER - TY - JOUR AU - Yamashita, H. AU - Nakayama, K. AU - Ishikawa, M. AU - Nakamura, K. AU - Ishibashi, T. AU - Sanuki, K. PY - 2018 DA - 2018// TI - Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer JO - Oncotarget VL - 9 ID - Yamashita2018 ER - TY - JOUR AU - Geiersbach, K. B. AU - Samowitz, W. S. PY - 2011 DA - 2011// TI - Microsatellite instability and colorectal cancer JO - Arch Pathol Lab Med VL - 135 UR - https://doi.org/10.5858/arpa.2011-0035-RA DO - 10.5858/arpa.2011-0035-RA ID - Geiersbach2011 ER - TY - JOUR AU - Zeinalian, M. AU - Hashemzadeh-Chaleshtori, M. AU - Salehi, R. AU - Emami, M. H. PY - 2018 DA - 2018// TI - Clinical aspects of microsatellite instability testing in colorectal Cancer JO - Adv Biomed Res VL - 7 UR - https://doi.org/10.4103/abr.abr_185_16 DO - 10.4103/abr.abr_185_16 ID - Zeinalian2018 ER - TY - JOUR AU - Xiao, X. AU - Dong, D. AU - He, W. AU - Song, L. AU - Wang, Q. AU - Yue, J. PY - 2018 DA - 2018// TI - Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer JO - Gynecol Oncol VL - 149 UR - https://doi.org/10.1016/j.ygyno.2018.02.009 DO - 10.1016/j.ygyno.2018.02.009 ID - Xiao2018 ER - TY - JOUR AU - Jin, Z. AU - Yoon, H. H. PY - 2016 DA - 2016// TI - The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 JO - J Gastrointest Oncol VL - 7 UR - https://doi.org/10.21037/jgo.2016.08.06 DO - 10.21037/jgo.2016.08.06 ID - Jin2016 ER - TY - JOUR AU - Kumar, R. AU - Yu, F. AU - Zhen, Y. H. AU - Li, B. AU - Wang, J. AU - Yang, Y. PY - 2017 DA - 2017// TI - PD-1 blockade restores impaired function of ex vivo expanded CD8(+) T cells and enhances apoptosis in mismatch repair deficient EpCAM(+)PD-L1(+) cancer cells JO - Onco Targets Ther VL - 10 UR - https://doi.org/10.2147/OTT.S130131 DO - 10.2147/OTT.S130131 ID - Kumar2017 ER - TY - JOUR AU - Le, D. T. AU - Durham, J. N. AU - Smith, K. N. AU - Wang, H. AU - Bartlett, B. R. AU - Aulakh, L. K. PY - 2017 DA - 2017// TI - Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade JO - Science VL - 357 UR - https://doi.org/10.1126/science.aan6733 DO - 10.1126/science.aan6733 ID - Le2017 ER - TY - JOUR AU - Mills, A. M. AU - Dill, E. A. AU - Moskaluk, C. A. AU - Dziegielewski, J. AU - Bullock, T. N. AU - Dillon, P. M. PY - 2018 DA - 2018// TI - The relationship between mismatch repair deficiency and PD-L1 expression in breast carcinoma JO - Am J Surg Pathol VL - 42 UR - https://doi.org/10.1097/PAS.0000000000000949 DO - 10.1097/PAS.0000000000000949 ID - Mills2018 ER - TY - JOUR AU - El Jabbour, T. AU - Ross, J. S. AU - Sheehan, C. E. AU - Affolter, K. E. AU - Geiersbach, K. B. AU - Boguniewicz, A. PY - 2018 DA - 2018// TI - PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry JO - J Clin Pathol VL - 71 UR - https://doi.org/10.1136/jclinpath-2017-204525 DO - 10.1136/jclinpath-2017-204525 ID - El Jabbour2018 ER - TY - JOUR AU - Jiang, L. AU - Su, X. AU - Zhang, T. AU - Yin, X. AU - Zhang, M. AU - Fu, H. PY - 2017 DA - 2017// TI - PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC) JO - Oncotarget VL - 8 ID - Jiang2017 ER - TY - JOUR AU - Li, X. AU - Lian, Z. AU - Wang, S. AU - Xing, L. AU - Yu, J. PY - 2018 DA - 2018// TI - Interactions between EGFR and PD-1/PD-L1 pathway: implications for treatment of NSCLC JO - Cancer Lett VL - 418 UR - https://doi.org/10.1016/j.canlet.2018.01.005 DO - 10.1016/j.canlet.2018.01.005 ID - Li2018 ER - TY - JOUR AU - Petrelli, F. AU - Maltese, M. AU - Tomasello, G. AU - Conti, B. AU - Borgonovo, K. AU - Cabiddu, M. PY - 2018 DA - 2018// TI - Clinical and molecular predictors of PD-L1 expression in non-small-cell lung Cancer: systematic review and meta-analysis JO - Clin Lung Cancer VL - 19 UR - https://doi.org/10.1016/j.cllc.2018.02.006 DO - 10.1016/j.cllc.2018.02.006 ID - Petrelli2018 ER - TY - JOUR AU - Lan, B. AU - Ma, C. AU - Zhang, C. AU - Chai, S. AU - Wang, P. AU - Ding, L. PY - 2018 DA - 2018// TI - Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis JO - Oncotarget VL - 9 ID - Lan2018 ER - TY - JOUR AU - Coelho, M. A. AU - de Carne, T. S. AU - Rana, S. AU - Zecchin, D. AU - Moore, C. AU - Molina-Arcas, M. PY - 2017 DA - 2017// TI - Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA JO - Immunity VL - 47 UR - https://doi.org/10.1016/j.immuni.2017.11.016 DO - 10.1016/j.immuni.2017.11.016 ID - Coelho2017 ER - TY - JOUR AU - Cha, Y. J. AU - Shim, H. S. PY - 2017 DA - 2017// TI - PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.20948 DO - 10.18632/oncotarget.20948 ID - Cha2017 ER - TY - JOUR AU - Boichard, A. AU - Tsigelny, I. F. AU - Kurzrock, R. PY - 2017 DA - 2017// TI - High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations JO - Oncoimmunology. VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1284719 DO - 10.1080/2162402X.2017.1284719 ID - Boichard2017 ER - TY - JOUR AU - Gadducci, A. AU - Guerrieri, M. E. PY - 2017 DA - 2017// TI - Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research JO - Anticancer Res VL - 37 ID - Gadducci2017 ER - TY - JOUR AU - Sacher, A. G. AU - Gandhi, L. PY - 2016 DA - 2016// TI - Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung Cancer: a review JO - JAMA Oncol. VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.0639 DO - 10.1001/jamaoncol.2016.0639 ID - Sacher2016 ER - TY - JOUR AU - Yi, M. AU - Yu, S. AU - Qin, S. AU - Liu, Q. AU - Xu, H. AU - Zhao, W. PY - 2018 DA - 2018// TI - Gut microbiome modulates efficacy of immune checkpoint inhibitors JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0592-6 DO - 10.1186/s13045-018-0592-6 ID - Yi2018 ER - TY - JOUR AU - Sivan, A. AU - Corrales, L. AU - Hubert, N. AU - Williams, J. B. AU - Aquino-Michaels, K. AU - Earley, Z. M. PY - 2015 DA - 2015// TI - Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy JO - Science VL - 350 UR - https://doi.org/10.1126/science.aac4255 DO - 10.1126/science.aac4255 ID - Sivan2015 ER - TY - JOUR AU - Gopalakrishnan, V. AU - Spencer, C. N. AU - Nezi, L. AU - Reuben, A. AU - Andrews, M. C. AU - Karpinets, T. V. PY - 2018 DA - 2018// TI - Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan4236 DO - 10.1126/science.aan4236 ID - Gopalakrishnan2018 ER - TY - JOUR AU - Routy, B. AU - Le Chatelier, E. AU - Derosa, L. AU - Duong, C. P. M. AU - Alou, M. T. AU - Daillere, R. PY - 2018 DA - 2018// TI - Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan3706 DO - 10.1126/science.aan3706 ID - Routy2018 ER - TY - JOUR AU - Daillere, R. AU - Vetizou, M. AU - Waldschmitt, N. AU - Yamazaki, T. AU - Isnard, C. AU - Poirier-Colame, V. PY - 2016 DA - 2016// TI - Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects JO - Immunity VL - 45 UR - https://doi.org/10.1016/j.immuni.2016.09.009 DO - 10.1016/j.immuni.2016.09.009 ID - Daillere2016 ER - TY - JOUR AU - Blacher, E. AU - Levy, M. AU - Tatirovsky, E. AU - Elinav, E. PY - 2017 DA - 2017// TI - Microbiome-modulated metabolites at the Interface of host immunity JO - J Immunol VL - 198 UR - https://doi.org/10.4049/jimmunol.1601247 DO - 10.4049/jimmunol.1601247 ID - Blacher2017 ER - TY - JOUR AU - Vetizou, M. AU - Pitt, J. M. AU - Daillere, R. AU - Lepage, P. AU - Waldschmitt, N. AU - Flament, C. PY - 2015 DA - 2015// TI - Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad1329 DO - 10.1126/science.aad1329 ID - Vetizou2015 ER - TY - STD TI - Mitsuhashi A, Okuma Y. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clin Transl Oncol. 2018; https://doi.org/10.1007/s12094-017-1827-7. ID - ref93 ER - TY - JOUR AU - Krieg, C. AU - Nowicka, M. AU - Guglietta, S. AU - Schindler, S. AU - Hartmann, F. J. AU - Weber, L. M. PY - 2018 DA - 2018// TI - High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4466 DO - 10.1038/nm.4466 ID - Krieg2018 ER - TY - JOUR AU - Kamphorst, A. O. AU - Pillai, R. N. AU - Yang, S. AU - Nasti, T. H. AU - Akondy, R. S. AU - Wieland, A. PY - 2017 DA - 2017// TI - Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients JO - Proc Natl Acad Sci U S A VL - 114 UR - https://doi.org/10.1073/pnas.1705327114 DO - 10.1073/pnas.1705327114 ID - Kamphorst2017 ER - TY - STD TI - Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, et al. Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population. Br J Dermatol. 2018; https://doi.org/10.1111/bjd.16427. ID - ref96 ER - TY - JOUR AU - Weide, B. AU - Martens, A. AU - Hassel, J. C. AU - Berking, C. AU - Postow, M. A. AU - Bisschop, K. PY - 2016 DA - 2016// TI - Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0127 DO - 10.1158/1078-0432.CCR-16-0127 ID - Weide2016 ER - TY - JOUR AU - Cabel, L. AU - Riva, F. AU - Servois, V. AU - Livartowski, A. AU - Daniel, C. AU - Rampanou, A. PY - 2017 DA - 2017// TI - Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx212 DO - 10.1093/annonc/mdx212 ID - Cabel2017 ER - TY - JOUR AU - Iijima, Y. AU - Hirotsu, Y. AU - Amemiya, K. AU - Higashi, S. AU - Miyashita, Y. AU - Omata, M. PY - 2017 DA - 2017// TI - Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days JO - Respir Med Case Rep VL - 22 ID - Iijima2017 ER - TY - JOUR AU - Lipson, E. J. AU - Velculescu, V. E. AU - Pritchard, T. S. AU - Sausen, M. AU - Pardoll, D. M. AU - Topalian, S. L. PY - 2014 DA - 2014// TI - Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade JO - J Immunother Cancer VL - 2 UR - https://doi.org/10.1186/s40425-014-0042-0 DO - 10.1186/s40425-014-0042-0 ID - Lipson2014 ER - TY - STD TI - Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. OncoImmunology. 2018; e1438111 ID - ref101 ER - TY - JOUR AU - Zhou, J. AU - Mahoney, K. M. AU - Giobbie-Hurder, A. AU - Zhao, F. AU - Lee, S. AU - Liao, X. PY - 2017 DA - 2017// TI - Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0329 DO - 10.1158/2326-6066.CIR-16-0329 ID - Zhou2017 ER - TY - JOUR AU - Kruger, S. AU - Legenstein, M. L. AU - Rosgen, V. AU - Haas, M. AU - Modest, D. P. AU - Westphalen, C. B. PY - 2017 DA - 2017// TI - Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer JO - Oncoimmunology. VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1310358 DO - 10.1080/2162402X.2017.1310358 ID - Kruger2017 ER - TY - JOUR AU - Nagato, T. AU - Ohkuri, T. AU - Ohara, K. AU - Hirata, Y. AU - Kishibe, K. AU - Komabayashi, Y. PY - 2017 DA - 2017// TI - Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy JO - Cancer Immunol Immunother VL - 66 UR - https://doi.org/10.1007/s00262-017-1987-x DO - 10.1007/s00262-017-1987-x ID - Nagato2017 ER - TY - JOUR AU - Caponnetto, S. AU - Iannantuono, G. M. AU - Barchiesi, G. AU - Magri, V. AU - Gelibter, A. AU - Cortesi, E. PY - 2017 DA - 2017// TI - Prolactin as a potential early predictive factor in metastatic non-small cell lung Cancer patients treated with Nivolumab JO - Oncology VL - 93 UR - https://doi.org/10.1159/000464328 DO - 10.1159/000464328 ID - Caponnetto2017 ER - TY - JOUR AU - Yamazaki, N. AU - Kiyohara, Y. AU - Uhara, H. AU - Iizuka, H. AU - Uehara, J. AU - Otsuka, F. PY - 2017 DA - 2017// TI - Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma JO - Cancer Sci VL - 108 UR - https://doi.org/10.1111/cas.13226 DO - 10.1111/cas.13226 ID - Yamazaki2017 ER - TY - JOUR AU - Wallin, J. J. AU - Bendell, J. C. AU - Funke, R. AU - Sznol, M. AU - Korski, K. AU - Jones, S. PY - 2016 DA - 2016// TI - Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12624 DO - 10.1038/ncomms12624 ID - Wallin2016 ER - TY - JOUR AU - Dirkx, A. E. AU - Oude Egbrink, M. G. AU - Castermans, K. AU - van der Schaft, D. W. AU - Thijssen, V. L. AU - Dings, R. P. PY - 2006 DA - 2006// TI - Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors JO - FASEB J VL - 20 UR - https://doi.org/10.1096/fj.05-4493com DO - 10.1096/fj.05-4493com ID - Dirkx2006 ER - TY - JOUR AU - Atkins, M. B. AU - Plimack, E. R. AU - Puzanov, I. AU - Fishman, M. N. AU - McDermott, D. F. AU - Cho, D. C. PY - 2018 DA - 2018// TI - Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30081-0 DO - 10.1016/S1470-2045(18)30081-0 ID - Atkins2018 ER - TY - JOUR AU - McKendry, R. T. AU - Spalluto, C. M. AU - Burke, H. AU - Nicholas, B. AU - Cellura, D. AU - Al-Shamkhani, A. PY - 2016 DA - 2016// TI - Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 Axis JO - Am J Respir Crit Care Med VL - 193 UR - https://doi.org/10.1164/rccm.201504-0782OC DO - 10.1164/rccm.201504-0782OC ID - McKendry2016 ER - TY - STD TI - Kameyama N, Chubachi S, Hegab AE, Yasuda H, Kagawa S, Tsutsumi A, et al. Intermittent exposure to cigarette smoke increases lung tumors and the severity of emphysema more than continuous exposure. Am J Respir Cell Mol Biol. 2018; https://doi.org/10.1165/rcmb.2017-0375OC. ID - ref111 ER - TY - JOUR AU - Gibbons, D. L. AU - Byers, L. A. AU - Kurie, J. M. PY - 2014 DA - 2014// TI - Smoking, p53 mutation, and lung cancer JO - Mol Cancer Res VL - 12 UR - https://doi.org/10.1158/1541-7786.MCR-13-0539 DO - 10.1158/1541-7786.MCR-13-0539 ID - Gibbons2014 ER - TY - JOUR AU - Faruki, H. AU - Mayhew, G. M. AU - Serody, J. S. AU - Hayes, D. N. AU - Perou, C. M. AU - Lai-Goldman, M. PY - 2017 DA - 2017// TI - Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.03.010 DO - 10.1016/j.jtho.2017.03.010 ID - Faruki2017 ER - TY - JOUR AU - Cortellini, A. AU - Bersanelli, M. AU - Buti, S. AU - Gambale, E. AU - Atzori, F. AU - Zoratto, F. PY - 2018 DA - 2018// TI - Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study JO - Immunotherapy VL - 10 UR - https://doi.org/10.2217/imt-2017-0167 DO - 10.2217/imt-2017-0167 ID - Cortellini2018 ER - TY - JOUR AU - Sun, C. AU - Mezzadra, R. AU - Schumacher, T. N. PY - 2018 DA - 2018// TI - Regulation and function of the PD-L1 checkpoint JO - Immunity VL - 48 UR - https://doi.org/10.1016/j.immuni.2018.03.014 DO - 10.1016/j.immuni.2018.03.014 ID - Sun2018 ER - TY - JOUR AU - Yamazaki, N. AU - Takenouchi, T. AU - Fujimoto, M. AU - Ihn, H. AU - Uchi, H. AU - Inozume, T. PY - 2017 DA - 2017// TI - Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) JO - Cancer Chemother Pharmacol VL - 79 UR - https://doi.org/10.1007/s00280-016-3237-x DO - 10.1007/s00280-016-3237-x ID - Yamazaki2017 ER - TY - JOUR AU - Bauml, J. AU - Seiwert, T. Y. AU - Pfister, D. G. AU - Worden, F. AU - Liu, S. V. AU - Gilbert, J. PY - 2017 DA - 2017// TI - Pembrolizumab for platinum- and Cetuximab-refractory head and neck Cancer: results from a single-arm JO - Phase II Study J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.1524 DO - 10.1200/JCO.2016.70.1524 ID - Bauml2017 ER - TY - JOUR AU - Hui, R. AU - Garon, E. B. AU - Goldman, J. W. AU - Leighl, N. B. AU - Hellmann, M. D. AU - Patnaik, A. PY - 2017 DA - 2017// TI - Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx008 DO - 10.1093/annonc/mdx008 ID - Hui2017 ER - TY - JOUR AU - Daud, A. I. AU - Wolchok, J. D. AU - Robert, C. AU - Hwu, W. J. AU - Weber, J. S. AU - Ribas, A. PY - 2016 DA - 2016// TI - Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody Pembrolizumab in melanoma JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.2477 DO - 10.1200/JCO.2016.67.2477 ID - Daud2016 ER - TY - JOUR AU - Horn, L. AU - Spigel, D. R. AU - Vokes, E. E. AU - Holgado, E. AU - Ready, N. AU - Steins, M. PY - 2017 DA - 2017// TI - Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.74.3062 DO - 10.1200/JCO.2017.74.3062 ID - Horn2017 ER - TY - JOUR AU - Sharma, P. AU - Retz, M. AU - Siefker-Radtke, A. AU - Baron, A. AU - Necchi, A. AU - Bedke, J. PY - 2017 DA - 2017// TI - Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30065-7 DO - 10.1016/S1470-2045(17)30065-7 ID - Sharma2017 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus Everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Rizvi, N. A. AU - Mazieres, J. AU - Planchard, D. AU - Stinchcombe, T. E. AU - Dy, G. K. AU - Antonia, S. J. PY - 2015 DA - 2015// TI - Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70054-9 DO - 10.1016/S1470-2045(15)70054-9 ID - Rizvi2015 ER - TY - JOUR AU - Motzer, R. J. AU - Rini, B. I. AU - McDermott, D. F. AU - Redman, B. G. AU - Kuzel, T. M. AU - Harrison, M. R. PY - 2015 DA - 2015// TI - Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.0703 DO - 10.1200/JCO.2014.59.0703 ID - Motzer2015 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. AU - McDermott, D. F. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Rittmeyer, A. AU - Barlesi, F. AU - Waterkamp, D. AU - Park, K. AU - Ciardiello, F. AU - von Pawel, J. PY - 2017 DA - 2017// TI - Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32517-X DO - 10.1016/S0140-6736(16)32517-X ID - Rittmeyer2017 ER - TY - JOUR AU - Balar, A. V. AU - Galsky, M. D. AU - Rosenberg, J. E. AU - Powles, T. AU - Petrylak, D. P. AU - Bellmunt, J. PY - 2017 DA - 2017// TI - Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32455-2 DO - 10.1016/S0140-6736(16)32455-2 ID - Balar2017 ER - TY - JOUR AU - McDermott, D. F. AU - Sosman, J. A. AU - Sznol, M. AU - Massard, C. AU - Gordon, M. S. AU - Hamid, O. PY - 2016 DA - 2016// TI - Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.7421 DO - 10.1200/JCO.2015.63.7421 ID - McDermott2016 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Fehrenbacher, L. AU - Spira, A. AU - Ballinger, M. AU - Kowanetz, M. AU - Vansteenkiste, J. AU - Mazieres, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Powles, T. AU - O'Donnell, P. H. AU - Massard, C. AU - Arkenau, H. T. AU - Friedlander, T. W. AU - Hoimes, C. J. PY - 2017 DA - 2017// TI - Efficacy and safety of Durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study JO - JAMA Oncol VL - 3 UR - https://doi.org/10.1001/jamaoncol.2017.2411 DO - 10.1001/jamaoncol.2017.2411 ID - Powles2017 ER - TY - JOUR AU - Apolo, A. B. AU - Infante, J. R. AU - Balmanoukian, A. AU - Patel, M. R. AU - Wang, D. AU - Kelly, K. PY - 2017 DA - 2017// TI - Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter JO - Phase Ib Study J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.6795 DO - 10.1200/JCO.2016.71.6795 ID - Apolo2017 ER - TY - JOUR AU - Matson, V. AU - Fessler, J. AU - Bao, R. AU - Chongsuwat, T. AU - Zha, Y. AU - Alegre, M. L. PY - 2018 DA - 2018// TI - The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients JO - Science VL - 359 UR - https://doi.org/10.1126/science.aao3290 DO - 10.1126/science.aao3290 ID - Matson2018 ER -